Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Harvard Bioscience (HBIO) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Harvard Bioscience (HBIO) over the last 16 years, with Q3 2025 value amounting to -$1.2 million.

  • Harvard Bioscience's Net Income towards Common Stockholders rose 7430.24% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.8 million, marking a year-over-year decrease of 27876.57%. This contributed to the annual value of -$12.4 million for FY2024, which is 26325.04% down from last year.
  • Harvard Bioscience's Net Income towards Common Stockholders amounted to -$1.2 million in Q3 2025, which was up 7430.24% from -$2.3 million recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's Net Income towards Common Stockholders peaked at $2.4 million during Q2 2022, and registered a low of -$50.3 million during Q1 2025.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$1.2 million (2023), whereas its average is -$4.2 million.
  • Within the past 5 years, the most significant YoY rise in Harvard Bioscience's Net Income towards Common Stockholders was 69390.24% (2022), while the steepest drop was 190294.12% (2022).
  • Over the past 5 years, Harvard Bioscience's Net Income towards Common Stockholders (Quarter) stood at $590000.0 in 2021, then tumbled by 466.78% to -$2.2 million in 2022, then rose by 15.99% to -$1.8 million in 2023, then surged by 102.75% to $50000.0 in 2024, then tumbled by 2568.0% to -$1.2 million in 2025.
  • Its Net Income towards Common Stockholders was -$1.2 million in Q3 2025, compared to -$2.3 million in Q2 2025 and -$50.3 million in Q1 2025.